Neurodegeneration

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

Retrieved on: 
Monday, January 17, 2022 - 10:04am
Neurodegeneration, Research, Patient, Frontotemporal dementia, ATTR, CSO, Discovery, Antibody, CNS, Parkinson's disease, Partnership, Ono, RTM, ALS, Therapy, Lewy body, Ono Pharmaceutical, Senior, Alzheimer's disease, Dementia, Amyotrophic lateral sclerosis, Pharmaceutical industry, Vaccine, Biogen

ZURICH, Jan. 17, 2022 Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.

Key Points: 
  • ZURICH, Jan. 17, 2022 Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.
  • In November 2017, Ono and Neurimmune signed a first drug discovery collaboration agreement to identify and develop human antibodies using the RTMtechnology platform.
  • In the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets.
  • "The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology."

DGAP-News: dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.

Retrieved on: 
Thursday, January 13, 2022 - 10:08pm
U.S. Securities and Exchange Commission, Vaccine, SAP, KfW, Biotechnology, Neurodegeneration, SEC, Gesellschaft mit beschränkter Haftung, Spanish mythology, Ownership, Nasdaq, DGAP, Supervisory board, DBH Deutsche Buch Handels GmbH & Co. KG, News, Therapy, Cancer, Hopp, CVAC, Kommanditgesellschaft, Securities Act of 1933, Federal republic, Investment, Security (finance), Property management, CureVac

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
  • dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
    WALLDORF / BERLIN , Germany - 13 January 2022 - Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt fr Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (Nasdaq: CVAC).
  • In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares.
  • Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS

Retrieved on: 
Thursday, January 13, 2022 - 3:38pm
Biomarker, Neurodegeneration, Coronavirus Scientific Advisory Board (Turkey), C9, Patient, ALS Functional Rating Scale - Revised, Clinical trial, Degenerative disease, Innovation, Population, Protein, Safety, Neuroscience, C9orf72, Disease, TFEB, GLOBE, Department, DNA, Deep learning, Intelligence, Evolutionism, Therapy, Pharmacokinetics, ALS, Butterfly network, Environment, Life expectancy, AI, Technology, Phase, National Medal, Vital capacity, Massachusetts General Hospital, PIKFYVE, Tesseract, Yale University, Amyotrophic lateral sclerosis, Pharmaceutical industry, Medical device, Genetics

GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase II study for a promising new approach to treat amyotrophic lateral sclerosis (ALS).

Key Points: 
  • GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation of a Phase II study for a promising new approach to treat amyotrophic lateral sclerosis (ALS).
  • AI Therapeutics drug candidate AIT-101 employs a novel approach to clearing toxic protein aggregates that accumulate in the brains of ALS patients and are a hallmark of the disease.
  • The potential therapeutic value for PIKfyve kinase inhibition in ALS and other neurodegenerative diseases was initially predicted by both the AI Therapeutics Guardian Angel Platform and by our own observations.
  • The Phase II clinical trial will use LAM-002A, the current formulation of the active ingredient of AIT-101.

Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application

Retrieved on: 
Thursday, January 13, 2022 - 1:00pm
Biomarker, Neurodegeneration, Forward-looking statement, Patient, SAN, Private Securities Litigation Reform Act, SEC, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Toxic shock syndrome, Eastern Time Zone, NASDAQ, GLOBE, IND, U.S. Securities and Exchange Commission, Traffic barrier, Therapy, BBB, Environment, ATV, Risk, Communication, Food, FDA, Investigational New Drug, Eastern, Security (finance), Pharmaceutical industry

The FDA indicated they will provide an official clinical hold letter to Denali in approximately 30 days.

Key Points: 
  • The FDA indicated they will provide an official clinical hold letter to Denali in approximately 30 days.
  • Denali plans to provide additional updates pending discussion with the FDA.
  • Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases.
  • Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement.

Quanterix Provides Operational and Preliminary Financial Highlights

Retrieved on: 
Thursday, January 13, 2022 - 12:30pm
Research, Pharmaceutical, Oncology, Technology, Infectious Diseases, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Other Technology, Health, Other Science, Research, Neurodegeneration, Private Securities Litigation Reform Act, Donanemab, Science, NASDAQ, Plasma, Neuro, Emergency Use Authorization, BBC, Efficiency, Diagnosis, Lilly, Telecommunication, Technology, Tau, Dementia, Conference, Publication, PET, Abbott, COVID-19, Risk, Eli Lilly, Infection, Company, Deloitte, Corporation, FDA, CCO, Lund, U.S. Securities and Exchange Commission, Forward-looking statement, Patient, News, Inflammation, Cardiology, Viral Research and Diagnostic Laboratories, Solution, EST, Roman Hrusovsky, Review, PST, Lund University, Biogen, Longevity, Antibody, Population, Quality of life, Pathology, Data, EMERGE, Neurology, Omicron, University, Interview, Pharmaceutical industry, Medical device, Medical imaging, Management

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.
  • Quanterix pTau-181 assay was granted Breakthrough Device Designation from the U.S. FDA as an aid in the diagnosis of Alzheimers disease.
  • Quanterix Simoa technology was highlighted in a record 465 new publications in 2021, bringing total Simoa-specific inclusions to over 1,585.
  • Hired President and CCO in 2021 to accelerate the operational scaling of Quanterix RUO opportunity and to catalyze the symbiotic relationship between Research and Diagnostic.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022 - 4:22am
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Pharmaceutical industry, Residential care, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022 - 4:11am
Neurodegeneration, ADAS, Patient, Dementia, Cognition, Neuroaid, Journal, Medical school, NeuroReport, Journal of the American Medical Directors Association, Brain, Department of Pharmacology, University College London, St. Luke's Hospital, Population, National University of Singapore, Ageing, Growth, DOI, Safety, American Medical Association, APP, National university, HIV disease progression rates, Alice Theadom, Department, Neuroprotection, AD, Alzheimer's disease, JAMDA, Caregiver, National University Health System, Diagnosis, Quality of life, Hospital, Associate professor, Neuropharmacology, FDA, SingHealth, Health insurance, Residential care, Pharmaceutical industry, Disease, Pharmacology

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

Retrieved on: 
Wednesday, January 12, 2022 - 2:56pm
U.S. Securities and Exchange Commission, PCR, Patient, Research, Technology, Cancer prevention, Legislation, Neurodegeneration, Biotechnology, Apoptosis, OTCQB, Cell cycle, COVID-19, Knowledge, Synthase, TBIA, Plasma, Solution, GLOBE, Lymphocyte, Cancer, NLC, Acquisition, Monocyte, Company, Method, Neuron, International joint venture, Immune system, TMB-2, Pressure, Todos, Brain, Alzheimer's disease, Pharmaceutical industry, Medical imaging

The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial.

Key Points: 
  • The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic.
  • The Companys proprietary therapeutic candidate Tollovir is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.

Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Retrieved on: 
Wednesday, January 12, 2022 - 2:21pm
MSA, Patient, Technology, Immunotherapy, Vaccine, University, Private Securities Litigation Reform Act, Mayo Clinic, EMA, Antibody, COVID-19, Migraine, Safety, University of Texas at Austin, DLB, Risk, Social media, Synucleinopathy, GLOBE, Neurodegeneration, The Michael J. Fox Foundation, Health, U.S. Securities and Exchange Commission, Time, Nasdaq, BBB, Company, Efficiency, Multiple system atrophy, Therapy, Conditional sentence, Hypercholesterolemia, Neuron, Alpha-synuclein, Protein misfolding cyclic amplification, Brain, Lewy body, Security (finance), Dementia, Pharmaceutical industry, CSF, Part, PD

We are delighted to achieve another milestone for Vaxxinity as we initiate the next part of our clinical program in Parkinsons, an indication with clear unmet needs for a large patient population, said Mei Mei Hu, Chief Executive Officer of Vaxxinity.

Key Points: 
  • We are delighted to achieve another milestone for Vaxxinity as we initiate the next part of our clinical program in Parkinsons, an indication with clear unmet needs for a large patient population, said Mei Mei Hu, Chief Executive Officer of Vaxxinity.
  • Developing vaccines that target chronic and difficult-to-treat diseases like Parkinsons are integral to our vision of providing cheaper, safer and more effective medicines to the world.
  • Parkinsons disease currently affects approximately one million people in the United States and more than 10 million people worldwide.
  • Clinical data from Part A of the Phase 1 trial indicate that UB-312 elicits antibody levels sufficient to cross the BBB (i.e., detectable in CSF).

PsychoGenics’ High Data Security Standards Are Certified by The NIH

Retrieved on: 
Wednesday, January 12, 2022 - 1:00pm
Mental Health, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, PTSD, Neurodegeneration, Analgesic, Research, NIH, Microdialysis, Risk assessment, Information, PGI, Contract, EEG, Muscular dystrophy, Government, Lists of diseases, National Institute of Neurological Disorders and Stroke, National Institute, PSPP, Industry, National, Program, Sunovion, NINDS, ALS, Psychology, Security, Autism, Depression, Therapy, AI, Epilepsy, Psychiatry, Electrophysiology, Molecular biology, Pharmaceutical industry, Pain

NIH contractors are required to conform to the standards of data/IT security established by the government, including access control, data recovery, auditing, and risk assessment, according to the content of the information produced, stored, and transmitted.

Key Points: 
  • NIH contractors are required to conform to the standards of data/IT security established by the government, including access control, data recovery, auditing, and risk assessment, according to the content of the information produced, stored, and transmitted.
  • PsychoGenics hardened all security protocols and will continue to pressure-test and monitor its information systems.
  • Meeting these security standards for our information systems assures our clients and partners that data shared with us, or produced by us, is handled with the highest standards in the industry.
  • PsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping.